2018
DOI: 10.1590/1806-9282.64.03.290 View full text |Buy / Rent full text
|
|

Abstract: Although there are differences between them, it was possible to establish a minimum core of conducts that may be useful in the daily practice of the physician.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
0
3
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

0
3
0
Order By: Relevance
“…While generally accepted as a suitable management option for low risk PCa, AS monitoring regime vary among clinical practices and guidelines, leading to it being questioned by some clinicians and patients [ 10 ]. In effort to minimise this, the Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) which has combined data from AS cohorts worldwide to create a global consensus for selection, monitoring and treatment intervention thresholds [ 11 ].…”
Section: Introductionmentioning
“…The value of 5.8 ng/mL of serum PSA is still surprising for a PC with LN metastases, the direct relationship between serum PSA value and PC extension being well known, only a small proportion of patients (about 5%) with PSA levels of 4.0–10.0 ng/mL having either seminal vesicle or LN involvement [ 18 ]. However, if the rectal resection had not been performed, PC would have remained undiagnosed in a relatively young patient, because Romania offers no implemented screening for PC detection, screening that address men above 50–55 years, according to most of the guidelines developed by the entities recommending the screening for PC [ 19 ]. The involvement of the rectum through PC can produce digestive symptoms such as constipation, alternating constipation and diarrhea, rectal bleeding [ 20 ], narrow stool, abdominal or rectal pain, the urgency of defecation, incontinence [ 21 ], all of can be wrongly attributed to a colonic tumor.…”
Section: ⧉ Discussionmentioning
“…It is important to note that, in some cases, it is possible to use the same antibodies to detect target molecules both in vivo by immuno-PET analysis and ex vivo by immunohistochemistry [24]. The treatment of breast and prostate cancers is based on immunohistochemical analysis of well-known prognostic markers such as ER, PR, Ki67, cerb2 (Figure 1), or PSA [25, 26]. Nevertheless, cancer cells frequently undergo selection during pharmacological treatment, hence possibly changing their dominant molecular phenotype and leading to drug resistance.…”
Section: Diagnostic Imaging and Anatomic Pathology: An Alliance Fomentioning